BIGBEAR
PHARMACEUTICAL
Palbociclib is the main component of breast cancer treatment medications and belongs to the class of cyclin-dependent kinase 4 and 6 inhibitors.
AuthenticGuaranteeFast DeliveryPrivacy On March 31, 2017, the U.S. Food and Drug Administration (FDA) granted palbociclib (IBRANCE, Pfizer) general approval for the treatment of hormone rec···【More】
Update: 08 Apr,2026Source: BigbearViews: 91
The U.S. Food and Drug Administration (FDA) has approved Ibrance (palbociclib) for the treatment of advanced (metastatic) breast cancer.Breast cancer ···【More】
Update: 08 Apr,2026Source: BigbearViews: 92
On March 31, 2017, the U.S. Food and Drug Administration (FDA) granted palbociclib (IBRANCE) general approval for the treatment of hormone receptor (H···【More】
Update: 08 Apr,2026Source: BigbearViews: 86
Pfizer and the German Breast Group (GBG) recently announced that the Phase 3 PENELOPE-B trial of Ibrance (trade name: palbociclib) for the treatment o···【More】
Update: 08 Apr,2026Source: BigbearViews: 90
Ibrance (palbociclib), developed by Pfizer, is the world's first CDK4/6 inhibitor to be marketed globally. It was first approved in February 2015 ···【More】
Update: 08 Apr,2026Source: BigbearViews: 84
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
